Date receipt dossier
Company / Sponsor
Sandoz Pharma, LTD
Phase
II
Indication category
Cancer therapy
Disease
Newly diagnosed or recurrent Glioblastoma multiforme
Therapeutic approach
Suicide gene/ pro drug
Genetic modification
Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)
Method of transfer of nucleic acid of interest
Amphotropic Murine Leukemia Virus
Administered biological material
Retroviral vector producing cells (PA 317)
Route of administration
Intratumoral
Locations in Belgium
Hôpital Erasme, Brussels
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
GLIB 201-E-00